NexgenRx Inc.
TSX VENTURE : NXG

NexgenRx Inc.

November 26, 2010 09:00 ET

NexgenRx Announces Amendments of Debentures

TORONTO, ONTARIO--(Marketwire - Nov. 26, 2010) - NEXGENRX INC. ("NexgenRx" or the "Corporation") (TSX VENTURE:NXG) announces that it has agreed to amend the conversion price of all $2,000,000 principal amount Debentures that were initially issued in October 2007 from $0.35 to $0.30. The Corporation also announces the amendment of its $500,000 principal amount Debenture that was initially issued in April 2007. The maturity date of the latter Debenture has been extended to November 26, 2011 and the interest rate payable thereunder has been amended from a fixed rate of 8% to a floating rate that is equal to the prime rate plus one percent (1%). No other terms of the Debentures have been amended. The TSX Venture Exchange has approved the foregoing amendments of the Debentures.

About NexgenRx

NexgenRx is a growing health benefits management company engaged in the design, management and administration of health benefit plans offered by employers and other plan sponsors for the benefit of their employees and plan members. More information on NexgenRx can be found at www.nexgenrx.com.

Caution Regarding Forward-Looking Statements – This news release contains certain forward-looking statements, including statements regarding the business and anticipated financial performance of the Corporation. These statements are subject to a number of risks and uncertainties. Actual results may differ materially from results contemplated by the forward-looking statements. When relying on forward-looking statements to make decisions, investors and others should carefully consider the foregoing factors and other uncertainties and should not place undue reliance on such forward-looking statements.

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of the release.

Contact Information

  • NexgenRx Inc.
    Ronald C. Loucks
    President and CEO
    (416) 695-3393 x 801
    (647) 722-2920 (FAX)
    www.nexgenrx.com